Editas Medicine, Inc. — Director's Dealing 2017

Sep 6, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Editas Medicine, Inc. (EDIT)
CIK: 0001650664
Period of Report: 2017-09-01

Reporting Person: Bosley Katrine (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-09-01	Common Stock	S	9800	$20.3991	Disposed	1414629	Direct
2017-09-01	Common Stock	S	200	$21.195	Disposed	1414429	Direct
2017-09-05	Common Stock	S	6666	$20.2042	Disposed	1407763	Direct

Footnotes

F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017.

F2: This transaction was executed in multiple trades at prices ranging from $20.09 to $21.06. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3: This transaction was executed in multiple trades at prices ranging from $21.13 to $21.26. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F4: This transaction was executed in multiple trades at prices ranging from $20.00 to $20.85. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.